• Alphatec Holdings (Carlsbad, California), the parent company of Alphatec Spine, congratulates Richard Ravitch on his appointment as Lieutenant Governor for the State of New York. Since June 2007, Ravitch has served on the board of Alphatec Holdings. Due to his appointment, Ravitch resigned his board seat with the company. Alphatec Spine makes products for the surgical treatment of spine disorders, with a focus on the aging spine.

• MicroMed Cardiovascular (Houston) has named Ash Attia VP of Asia-Pacific. Most recently, Attia was VP of Asia-Pacific for Ventracor Limited. MicroMed Cardiovascular makes the HeartAssist 5 left ventricular assist device.

Todd Wallach was named CEO of Molecular Detection (MDI; Wayne, Pennsylvania). Previously, Wallach was CFO of Aton Pharma. MDI makes a portfolio of "sample-to-answer" Detect-Ready molecular diagnostic tests for the detection of infectious diseases.

• Ocular Therapeutix (Waltham, Massachusetts) reported the expansion of its board with the appointment of Daniel Myers and Bernard Haffey. Myers is currently the president/CEO and co-founder of Alimera Sciences; Haffey was most recently president/CEO of NDO Surgical. Ocular Therapeutix specializes in ophthalmic therapeutic products using its proprietary hydrogel technology.

• Phadia (Portage, Michigan) said that David Esposito has been promoted to president/GM. Esposito joined Phadia earlier this year as senior VP of U.S. Sales and Marketing. Phadia makes allergy and autoimmunity in vitro diagnostic products.

• Premier Research Group Limited (Philadelphia) reported the promotion of its current COO, Troy McCall, PhD, to CEO. Premier Research Group is a contract research organization specializing in therapeutic focus and operational expertise to deliver clinical trial services for biopharmaceutical and medical device companies.